## Core Concept
The question assesses knowledge of prognostic markers in breast cancer (CA Breast). Prognostic markers help predict the likely outcome of the disease and guide treatment decisions. These markers can include tumor characteristics, molecular profiles, and clinical factors.

## Why the Correct Answer is Right
Option is the correct answer because **HER2 positivity** and **hormone receptor (estrogen receptor (ER) and progesterone receptor (PR)) positivity** are generally associated with a better prognosis compared to HER2 negative and triple-negative breast cancers, especially with the advent of targeted therapies like trastuzumab for HER2-positive tumors and endocrine therapy for hormone receptor-positive tumors.

## Why Each Wrong Option is Incorrect
- **Option A:** Tumor size > 5 cm is a poor prognostic marker because larger tumors are more likely to have metastasized and are associated with a worse outcome.
- **Option B:** Presence of lymph node metastasis is a poor prognostic marker as it indicates the spread of cancer beyond the original site, correlating with a higher risk of recurrence and mortality.
- **Option D:** High histological grade is a poor prognostic marker. High-grade tumors tend to grow and spread faster than low-grade tumors, leading to a worse prognosis.

## Clinical Pearl / High-Yield Fact
A key clinical pearl is that **HER2-positive and hormone receptor-positive breast cancers**, while aggressive, have significantly improved prognoses with targeted therapies. This contrasts with **triple-negative breast cancers**, which lack these receptors and have a poorer prognosis due to the absence of targeted therapies.

## Correct Answer: C.